Patients with psoriatic arthritis who meet clinical criteria for minimal disease activity also tend to report good disease ...

The most recent AAD/National Psoriasis Foundation (NPF) clinical guidelines, published from 2019 to 2021, consist of six sections and more than 200 journal pages.

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

For patients with psoriasis and Type 2 diabetes, the risk of developing chronic kidney disease (CKD) continued to rise ...

Skin diseases contribute significantly to morbidity worldwide, yet their burden in North Africa and the Middle East (NAME) remains poorly understood. This study aims to assess the burden of skin ...

Tumor necrosis factor (TNF) inhibitor therapy was effective in reducing the likelihood that psoriasis would progress to psoriatic arthritis (PsA), a retrospective study indicated. Among ...

Psoriasis can occur near the eyes, causing redness, itching, dryness, and flaking skin. Once it’s correctly diagnosed, you can often manage it with topical treatments.

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Psoriasis, a skin condition, can put your vision at risk — here’s what to do to help protect your eyesight and keep seeing clearly.

Activated T cells secrete cytokines, which are important in mediating the growth, development, and activation of cells of the immune system (Haynes & Fauci, 2001). Two types of helper T cells (CD4 ...

This study's main exposure was to dupilumab in comparison to other systemic drugs, such as methotrexate, cyclosporine, corticosteroids, azathioprine, or mycophenolate mofetil. Incident psoriasis was ...

Psoriasis is a chronic, inflammatory, hyperproliferative skin disease with an etiology and pathogenesis that have undergone intense investigation during the past decade.